UBS Group’s Annovis Bio ANVS Stock Holding History

UBS Group’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-25,000	Closed	-$144K	–	9476
2024 Q2	$144K	Buy	+25,000	New	+$203K	﹤0.01%	5899

Other funds holding ANVS

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

UBS Group's ANVS Position: Q1 2026 in Review

UBS Group reduced its Annovis Bio (ANVS) stake by 30% in Q1 2026, selling an estimated $25K and leaving 21,538 shares worth $48K. The position accounts for ﹤0.01% of the portfolio, ranked #7394.

UBS Group first reported a position in ANVS in Q2 2021 and has held it in 16 quarters since. The position peaked at $245K in Q4 2024. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

UBS Group held 21,538 shares of Annovis Bio worth $48K as of Q1 2026.
UBS Group sold 9,105 Annovis Bio shares in Q1 2026, an estimated $25K.
Annovis Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7394 holding.
UBS Group first reported a position in Annovis Bio in Q2 2021 and has held it in 16 quarters since.
UBS Group's Annovis Bio position peaked at $245K in Q4 2024.
56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.